Advertisement

Considerations for Medications Commonly Utilized in the Oncology Population in the Intensive Care Unit

  • Anne Rain Tanner BrownEmail author
  • Michelle Horng
  • Terri Lynn Shigle
Living reference work entry

Abstract

An increasing number of oncologic patients are presenting to the intensive care unit with complications from both their chronic disease states and cancer therapies due to improved survival rates. The management of these patients is complex due to immunosuppression (from the malignancy and/or treatment), metabolic complications, and diverse medication regimens with the potential for significant drug-drug interactions and overlapping adverse effects. This chapter will provide clinicians with an overview of non-chemotherapy medications frequently encountered in the critically ill oncologic patient, with a focus on practical considerations.

Keywords

Oncology Critical care Cancer Drug interactions Pharmacology Intensive care Critically ill Drug monitoring Adverse events Immunocompromised 

References

  1. 1.
    Abouelnasr A, Roy J, Cohen S, Kiss T, Lachance S. Defining the role of sirolimus in the management of graft-versus-host disease: from prophylaxis to treatment. Biol Blood Marrow Transplant. 2013;19(1):12–21.  https://doi.org/10.1016/j.bbmt.2012.06.020.CrossRefPubMedGoogle Scholar
  2. 2.
    Afessa B, Tefferi A, Litzow MR, Peters SG. Outcome of diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. Am J Respir Crit Care Med. 2002;166(10):1364–8.  https://doi.org/10.1164/rccm.200208-792OC.CrossRefPubMedGoogle Scholar
  3. 3.
    Amgen Inc. Nplate (romiplostim) [package insert]. Thousand Oaks; 2008.Google Scholar
  4. 4.
    Amgen Inc. Xgeva (denosumab) [package insert]. Thousand Oaks; 2013.Google Scholar
  5. 5.
    Amgen Inc. Neulasta (pegfilgrastim) [package insert]. Thousand Oaks; 2015a.Google Scholar
  6. 6.
    Amgen Inc. Neupogen (filgrastim) [package insert]. Thousand Oaks; 2015b.Google Scholar
  7. 7.
    Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ. Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. Cancer. 2013;119(21):3784–7.  https://doi.org/10.1002/cncr.28253.CrossRefPubMedGoogle Scholar
  8. 8.
    Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014;69(5):1162–76.  https://doi.org/10.1093/jac/dkt508.CrossRefPubMedGoogle Scholar
  9. 9.
    Astellas Pharma. Prograf (tacrolimus) [package insert]. Deerfield; 2012.Google Scholar
  10. 10.
    Astellas Pharma. Cresemba (Isavuconazonium sulfate) [package insert]. Northbrook; 2015.Google Scholar
  11. 11.
    Baden LR, Swaminathan S, Almyroudis NG, Angarone M, Blouin G, Camins BC, Cooper B, Dubberke ER, Engemann AM, Freifeld AG, Greene JN, Gregg K, Hakim H, Ito. IJ, Lustberg ME, Mones JV, Pergam S, Rolston K, Satyanarayana G, Schulz L, Seo SK, Shoham S, Taplitz R, Topal J, Wilson JW. Prevention and treatment of cancer-related infections, Version 1.2018. NCCN Clinical Practice Guidelines in Oncology; 2018.Google Scholar
  12. 12.
    Baker MS, Diab KJ, Carlos WG, Mathur P. Intrapulmonary recombinant factor VII as an effective treatment for diffuse alveolar hemorrhage: a case series. J Bronchol Intervent Pulmonol. 2016;23(3):255–8.  https://doi.org/10.1097/lbr.0000000000000286.CrossRefGoogle Scholar
  13. 13.
    Ben Venue Laboratories I. Aredia (pamidronate) [package insert]. Bedford; 2009.Google Scholar
  14. 14.
    Blackburn LM, Tverdek FP, Hernandez M, Bruno JJ. First-dose pharmacokinetics of aminoglycosides in critically ill haematological malignancy patients. Int J Antimicrob Agents. 2015;45(1):46–53.  https://doi.org/10.1016/j.ijantimicag.2014.09.006.CrossRefPubMedGoogle Scholar
  15. 15.
    Blackman A, Boutin A, Shimanovsky A, Baker WJ, Forcello N. Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: a case report and review of the literature. J Oncol Pharm Pract. 2017;  https://doi.org/10.1177/1078155217710714.CrossRefGoogle Scholar
  16. 16.
    Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113(23):5711–9.  https://doi.org/10.1182/blood-2008-10-143560.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 2013;54(1):11–27.  https://doi.org/10.1111/j.1528-1167.2012.03671.x.CrossRefPubMedGoogle Scholar
  18. 18.
    Brody SR, Humphreys MH, Gambertoglio JG, Schoenfeld P, Cundy KC, Aweeka FT. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis. Clin Pharmacol Ther. 1999;65(1):21–8.  https://doi.org/10.1016/s0009-9236(99)70118-9.CrossRefPubMedGoogle Scholar
  19. 19.
    Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, Laroche SM, Riviello JJ Jr, Shutter L, Sperling MR, Treiman DM, Vespa PM. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3–23.  https://doi.org/10.1007/s12028-012-9695-z.CrossRefPubMedGoogle Scholar
  20. 20.
    Cairo MS, Coiffier B, Reiter A, Younes A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010;149(4):578–86.  https://doi.org/10.1111/j.1365-2141.2010.08143.x.CrossRefPubMedGoogle Scholar
  21. 21.
    Casper C, Englund J, Boeckh M. How I treat influenza in patients with hematologic malignancies. Blood. 2010;115(7):1331–42.  https://doi.org/10.1182/blood-2009-11-255455.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Chemaly RF, Aitken SL, Wolfe CR, Jain R, Boeckh MJ. Aerosolized ribavirin: the most expensive drug for pneumonia. Transpl Infect Dis. 2016;18(4):634–6.  https://doi.org/10.1111/tid.12551.CrossRefPubMedGoogle Scholar
  23. 23.
    Chemaly RF, Shah DP, Boeckh MJ. Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014;59(Suppl 5):S344–51.  https://doi.org/10.1093/cid/ciu623.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Cho SY, Lee DG, Choi SM, Park C, Chun HS, Park YJ, Choi JK, Lee HJ, Park SH, Choi JH, Yoo JH. Stenotrophomonas maltophilia bloodstream infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations. BMC Infect Dis. 2015;15:69.  https://doi.org/10.1186/s12879-015-0801-7.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26(16):2767–78.  https://doi.org/10.1200/jco.2007.15.0177.CrossRefPubMedGoogle Scholar
  26. 26.
    Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2014;25(Suppl 3):iii124–37.  https://doi.org/10.1093/annonc/mdu103.CrossRefPubMedGoogle Scholar
  27. 27.
    Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, Guinan E, Vogelsang G, Krishnan A, Giralt S, Revta C, Carreau NA, Iacobelli M, Carreras E, Ruutu T, Barbui T, Antin JH, Niederwieser D. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16(2):157–68.  https://doi.org/10.1016/j.bbmt.2009.08.024.CrossRefPubMedGoogle Scholar
  28. 28.
    Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, Lanternier F, Pagano L, Skiada A, Akova M, Arendrup MC, Boekhout T, Chowdhary A, Cuenca-Estrella M, Freiberger T, Guinea J, Guarro J, de Hoog S, Hope W, Johnson E, Kathuria S, Lackner M, Lass-Florl C, Lortholary O, Meis JF, Meletiadis J, Munoz P, Richardson M, Roilides E, Tortorano AM, Ullmann AJ, van Diepeningen A, Verweij P, Petrikkos G. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;20(Suppl 3):5–26.  https://doi.org/10.1111/1469-0691.12371.CrossRefPubMedGoogle Scholar
  29. 29.
    Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–59.  https://doi.org/10.1056/NEJMoa061094.CrossRefPubMedGoogle Scholar
  30. 30.
    Corp. MSD. Prevymis (letermovir) [package insert]. Whitehouse Station; 2017.Google Scholar
  31. 31.
    Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I, Griffiths EA, Hough S, Kloth DD, Kuter DJ, Lyman GH, Mably M, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Roy V, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Talbott M, Vadhan-Raj S, Vasu S, Wadleigh M, Westervelt P, Burns JL, Pluchino L. Myeloid growth factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2017;15(12):1520–41.  https://doi.org/10.6004/jnccn.2017.0175.CrossRefGoogle Scholar
  32. 32.
    Crothers K, Furrer H, Helweg-Larsen J, Huang L, Kovacs J, Miller R, Morris A (2017) Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed 19 Apr 2018.
  33. 33.
    Cruciani M, Rampazzo R, Malena M, Lazzarini L, Todeschini G, Messori A, Concia E. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis. 1996;23(4):795–805.CrossRefGoogle Scholar
  34. 34.
    Crumpacker C, Zhang J. Cytomegalovirus. In: Mandell G, Bennett J, Dolin R, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 7th ed. Philadelphia: Elsevier; 2010. p. 1971–87.CrossRefGoogle Scholar
  35. 35.
    Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E, Revta C, Ebert R, Warren D, Choi S, Koreth J, Armand P, Alyea E, Carter S, Horowitz M, Antin JH, Soiffer R. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008;112(12):4425–31.  https://doi.org/10.1182/blood-2008-07-169342.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Dalle JH, Giralt SA. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transplant. 2016;22(3):400–9.  https://doi.org/10.1016/j.bbmt.2015.09.024.CrossRefPubMedGoogle Scholar
  37. 37.
    Diri R, Anwer F, Yeager A, Krishnadasan R, McBride A. Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2016;18(1):63–9.  https://doi.org/10.1111/tid.12486.CrossRefPubMedGoogle Scholar
  38. 38.
    El Chaer F, Shah DP, Chemaly RF. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. Blood. 2016;128(23):2624–36.  https://doi.org/10.1182/blood-2016-06-688432.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Escuissato DL, Warszawiak D, Marchiori E. Differential diagnosis of diffuse alveolar haemorrhage in immunocompromised patients. Curr Opin Infect Dis. 2015;28(4):337–42.  https://doi.org/10.1097/qco.0000000000000181.CrossRefPubMedGoogle Scholar
  40. 40.
    Exela Pharma Sciences. Ganciclovir [package insert]. Lenoir; 2017.Google Scholar
  41. 41.
    Falci DR, Pasqualotto AC. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist. 2013;6:163–74.  https://doi.org/10.2147/idr.S51340.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Foolad F, Aitken S, Shigle T. Use of oral ribavirin for the treatment of RSV Infections in Hematopoietic Cell Transplant Recipients. Paper presented at the ID Week; 2017.Google Scholar
  43. 43.
    Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56–93.  https://doi.org/10.1093/cid/cir073.CrossRefPubMedGoogle Scholar
  44. 44.
    Fresenius Kabi. Decadron (dexamethasone sodium phosphate) [package insert]. Lake Zurich; 2014.Google Scholar
  45. 45.
    Fukuda T, Hackman RC, Guthrie KA, Sandmaier BM, Boeckh M, Maris MB, Maloney DG, Deeg HJ, Martin PJ, Storb RF, Madtes DK. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood. 2003;102(8):2777–85.  https://doi.org/10.1182/blood-2003-05-1597.CrossRefPubMedGoogle Scholar
  46. 46.
    Galvin R, Brathen G, Ivashynka A, Hillbom M, Tanasescu R, Leone MA. EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. Eur J Neurol. 2010;17(12):1408–18.  https://doi.org/10.1111/j.1468-1331.2010.03153.x.CrossRefPubMedGoogle Scholar
  47. 47.
    Garnacho-Montero J, Diaz-Martin A, Canton-Bulnes L, Ramirez P, Sierra R, Arias-Verdu D, Rodriguez-Delgado M, Loza-Vazquez A, Rodriguez-Gomez J, Gordon M, Estella A, Garcia-Garmendia JL. Initial antifungal strategy reduces mortality in critically ill patients with candidemia: a propensity score-adjusted analysis of a multicenter study. Crit Care Med. 2018;46(3):384–93.  https://doi.org/10.1097/ccm.0000000000002867.CrossRefPubMedGoogle Scholar
  48. 48.
    Genentech I. Actemra (tocilizumab) [package insert]. South San Francisco: Genentech, Inc; 2018.Google Scholar
  49. 49.
    Genentech USA I. Copegus (ribavirin) [package insert]. South San Francisco; 2011.Google Scholar
  50. 50.
    Gerber B, Guggenberger R, Fasler D, Nair G, Manz MG, Stussi G, Schanz U. Reversible skeletal disease and high fluoride serum levels in hematologic patients receiving voriconazole. Blood. 2012;120(12):2390–4.  https://doi.org/10.1182/blood-2012-01-403030.CrossRefPubMedGoogle Scholar
  51. 51.
    Gilbert D. Aminoglycosides. In: Mandell GLBJ, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. New York: Churchill Livingston; 2000. p. 307–35.Google Scholar
  52. 52.
    Gilead Sciences I. Tamiflu (oseltamivir phosphate) [package insert]. Foster City; 2008.Google Scholar
  53. 53.
    Gilead Sciences I. Vistide (cidofovir injection) [package insert]. Foster City; 2010.Google Scholar
  54. 54.
    GlaxoSmithKline. Zovirax (acyclovir) [package insert]. Research Triangle Park; 2003.Google Scholar
  55. 55.
    Goldner W. Cancer-related hypercalcemia. J Oncol Pract. 2016;12(5):426–32.  https://doi.org/10.1200/jop.2016.011155.CrossRefPubMedGoogle Scholar
  56. 56.
    Greenberg RN, Mullane K, van Burik JA, Raad I, Abzug MJ, Anstead G, Herbrecht R, Langston A, Marr KA, Schiller G, Schuster M, Wingard JR, Gonzalez CE, Revankar SG, Corcoran G, Kryscio RJ, Hare R. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006;50(1):126–33.  https://doi.org/10.1128/aac.50.1.126-133.2006.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Grewal J, Grewal HK, Forman AD. Seizures and epilepsy in cancer: etiologies, evaluation, and management. Curr Oncol Rep. 2008;10(1):63–71.CrossRefGoogle Scholar
  58. 58.
    Gupta SK, Kantesaria B, Glue P. Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients. Eur J Clin Pharmacol. 2012;68(4):415–8.  https://doi.org/10.1007/s00228-011-1137-x.CrossRefPubMedGoogle Scholar
  59. 59.
    Gupta SK, Kantesaria B, Glue P. Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment. Drug Discov Ther. 2013;7(4):158–63.PubMedGoogle Scholar
  60. 60.
    Gupta SK, Kantesaria B, Glue P. Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosing. Drug Discoveries & Therapeutics. 2014;8(2):89–95.CrossRefGoogle Scholar
  61. 61.
    Hamadani M, Awan F. Role of thiamine in managing ifosfamide-induced encephalopathy. J Oncol Pharm Pract. 2006;12(4):237–9.  https://doi.org/10.1177/1078155206073553.CrossRefPubMedGoogle Scholar
  62. 62.
    Hankerson MJ, Raffetto B, Mallon WK, Shoenberger JM. Nebulized tranexamic acid as a noninvasive therapy for cancer-related hemoptysis. J Palliat Med. 2015;18(12):1060–2.  https://doi.org/10.1089/jpm.2015.0167.CrossRefPubMedGoogle Scholar
  63. 63.
    Holly P, Lisa L, Plamenova I, Dobrotova M, Kubisz P. Recombinant activated factor VII as an additional agent in the management of bleeding in patients with chemotherapy-induced thrombocytopenia. Blood transfus. 2013;11(3):466–8.  https://doi.org/10.2450/2012.0077-12.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Hospira Inc. Amicar (aminocaproic acid) [package insert]. Lake Forest; 2017.Google Scholar
  65. 65.
    Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471–82.  https://doi.org/10.1634/theoncologist.2015-0164.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Imbach P, Crowther M. Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med. 2011;365(8):734–41.  https://doi.org/10.1056/NEJMct1014202.CrossRefPubMedGoogle Scholar
  67. 67.
    Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis. 2006;42(5):597–607.  https://doi.org/10.1086/500139.CrossRefPubMedGoogle Scholar
  68. 68.
    Janssen Biotech I. Sylvant (siltuximab) [package insert]. Horsham; 2017.Google Scholar
  69. 69.
    Jazz Pharmaceuticals I. Defitelio (defibrotide) [package insert]. Palo Alto; 2016.Google Scholar
  70. 70.
    Kantrow SP, Hackman RC, Boeckh M, Myerson D, Crawford SW. Idiopathic pneumonia syndrome: changing spectrum of lung injury after marrow transplantation. Transplantation. 1997;63(8):1079–86.CrossRefGoogle Scholar
  71. 71.
    Kim S-H, Kwon J-C, Choi S-M, Lee D-G, Park SH, Choi J-H, Yoo J-H, Cho B-S, Eom K-S, Kim Y-J, Kim H-J, Lee S, Min C-K, Cho S-G, Kim D-W, Lee J-W, Min W-S. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome. Ann Hematol. 2013;92(4):533–41.  https://doi.org/10.1007/s00277-012-1631-y.CrossRefPubMedGoogle Scholar
  72. 72.
    Kostakou E, Rovina N, Kyriakopoulou M, Koulouris NG, Koutsoukou A. Critically ill cancer patient in intensive care unit: issues that arise. J Crit Care. 2014;29(5):817–22.  https://doi.org/10.1016/j.jcrc.2014.04.007.CrossRefPubMedGoogle Scholar
  73. 73.
    Kuo SH, Debnam JM, Fuller GN, de Groot J. Wernicke’s encephalopathy: an underrecognized and reversible cause of confusional state in cancer patients. Oncology. 2009;76(1):10–8.  https://doi.org/10.1159/000174951.CrossRefPubMedGoogle Scholar
  74. 74.
    Kuter DJ. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med. 2009;60:193–206.CrossRefGoogle Scholar
  75. 75.
    Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Williston Park). 2015;29(4):282–94.Google Scholar
  76. 76.
    Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH Jr, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrere F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet (London, England). 2008;371(9610):395–403.  https://doi.org/10.1016/s0140-6736(08)60203-2.CrossRefGoogle Scholar
  77. 77.
    Lara AR, Schwarz MI. Diffuse alveolar hemorrhage. Chest. 2010;137(5):1164–71.  https://doi.org/10.1378/chest.08-2084.CrossRefPubMedGoogle Scholar
  78. 78.
    Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A, Kern WV. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer. 2006;107(8):1743–51.  https://doi.org/10.1002/cncr.22205.CrossRefPubMedGoogle Scholar
  79. 79.
    Lewis ID, DeFor T, Weisdorf DJ. Increasing incidence of diffuse alveolar hemorrhage following allogeneic bone marrow transplantation: cryptic etiology and uncertain therapy. Bone Marrow Transplant. 2000;26(5):539–43.  https://doi.org/10.1038/sj.bmt.1702546.CrossRefPubMedGoogle Scholar
  80. 80.
    Lindemans CA, Leen AM, Boelens JJ. How I treat adenovirus in hematopoietic stem cell transplant recipients. Blood. 2010;116(25):5476–85.  https://doi.org/10.1182/blood-2010-04-259291.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Loblaw DA, Perry J, Chambers A, Laperriere NJ. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative’s Neuro-Oncology Disease Site Group. J Clin Oncol. 2005;23(9):2028–37.  https://doi.org/10.1200/jco.2005.00.067.CrossRefPubMedGoogle Scholar
  82. 82.
    Ltd. CH. Foscavir (foscarnet sodium) [package insert]. DE14 2WW, UK; 2011.Google Scholar
  83. 83.
    Marshall AL, Goodarzi K, Kuter DJ. Romiplostim in the management of the thrombocytopenic surgical patient. Transfusion. 2015;55(10):2505–10.  https://doi.org/10.1111/trf.13181.CrossRefPubMedGoogle Scholar
  84. 84.
    Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, Haider S, Ullmann AJ, Katayama Y, Brown J, Mullane KM, Boeckh M, Blumberg EA, Einsele H, Snydman DR, Kanda Y, DiNubile MJ, Teal VL, Wan H, Murata Y, Kartsonis NA, Leavitt RY, Badshah C. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433–44.  https://doi.org/10.1056/NEJMoa1706640.CrossRefPubMedGoogle Scholar
  85. 85.
    Metcalf JP, Rennard SI, Reed EC, Haire WD, Sisson JH, Walter T, Robbins RA. Corticosteroids as adjunctive therapy for diffuse alveolar hemorrhage associated with bone marrow transplantation. University of Nebraska Medical Center Bone Marrow Transplant Group. Am J Med. 1994;96(4):327–34.CrossRefGoogle Scholar
  86. 86.
    Miao J, Leblebjian H, Fowler-Scullion B, Parnes A. Single-center experience with Romiplostim for management of chemotherapy-induced thrombocytopenia (CIT). Blood. 2016;128:530.Google Scholar
  87. 87.
    Mielcarek M, Furlong T, Storer BE, Green ML, McDonald GB, Carpenter PA, Flowers ME, Storb R, Boeckh M, Martin PJ. Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial. Haematologica. 2015;100(6):842–8.  https://doi.org/10.3324/haematol.2014.118471.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Mintzer S, Mattson RT. Should enzyme-inducing antiepileptic drugs be considered first-line agents? Epilepsia. 2009;50(Suppl 8):42–50.  https://doi.org/10.1111/j.1528-1167.2009.02235.x.CrossRefPubMedGoogle Scholar
  89. 89.
    Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155(1):93–9.CrossRefGoogle Scholar
  90. 90.
    Mylan Institutional LLC. Miacalcin (calcitonin) [product insert]. Rockford; 2016.Google Scholar
  91. 91.
    Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47–62.  https://doi.org/10.1038/nrclinonc.2017.148.CrossRefPubMedGoogle Scholar
  92. 92.
    Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39(3):650–5.CrossRefGoogle Scholar
  93. 93.
    Novartis Pharmaceuticals Corporation. Sandimmune (cyclosporine capsules, oral solution, injection) [package insert]. East Hanover; 2015.Google Scholar
  94. 94.
    Novartis Pharmaceuticals Corporation. Zometa (zoledronic acid) [package insert]. East Hanover; 2016.Google Scholar
  95. 95.
    Novo Nordisk Inc. NovoSeven (coagulation factor VIIa) [package insert]. Princeton; 2006.Google Scholar
  96. 96.
    Ojeda E, Carca-Marco JA, Navarro B, Delalglesia A, Fores R, Bautista G, Krsnik I, Sanchez-Guerrero A, Sanjuan I, Regidor C, Gonzalo-Daganzo R, Martin-Donaire T, Sanchez R, Bravo G, Claros N, Cabero M, Beltran P, Cabrera JR. Use of romiplostim to facilitate platelet engraftment in allogeneic hematopoietic transplantation. Blood. 2011;118:1947.Google Scholar
  97. 97.
    Pagkalis S, Mantadakis E, Mavros MN, Ammari C, Falagas ME. Pharmacological considerations for the proper clinical use of aminoglycosides. Drugs. 2011;71(17):2277–94.  https://doi.org/10.2165/11597020-000000000-00000.CrossRefPubMedGoogle Scholar
  98. 98.
    Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. Clinical Practice Guideline for the Management of Candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–50.  https://doi.org/10.1093/cid/civ933.CrossRefPubMedGoogle Scholar
  99. 99.
    Paquette F, Bernier-Jean A, Brunette V, Ammann H, Lavergne V, Pichette V, Troyanov S, Bouchard J. Acute kidney injury and renal recovery with the use of aminoglycosides: a large retrospective study. Nephron. 2015;131(3):153–60.  https://doi.org/10.1159/000440867.CrossRefPubMedGoogle Scholar
  100. 100.
    Pathak V, Kuhn J, Gabriel D, Barrow J, Jennette JC, Henke DC. Use of activated factor VII in patients with diffuse alveolar hemorrhage: a 10 years institutional experience. Lung. 2015;193(3):375–9.  https://doi.org/10.1007/s00408-015-9720-z.CrossRefPubMedGoogle Scholar
  101. 101.
    Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–e60.  https://doi.org/10.1093/cid/ciw326.CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2006;57(2):176–89.  https://doi.org/10.1093/jac/dki448.CrossRefPubMedGoogle Scholar
  103. 103.
    Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prove A, Vermorken JB. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000;82(2):291–4.  https://doi.org/10.1054/bjoc.1999.0917.CrossRefPubMedPubMedCentralGoogle Scholar
  104. 104.
    Pennington CA, Park JM. Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients. Am J Health Syst Pharm. 2015;72(4):277–84.  https://doi.org/10.2146/ajhp140322.CrossRefPubMedGoogle Scholar
  105. 105.
    Pfizer. Cyklokapron (tranexamic acid) [package insert]. New York; 2011a.Google Scholar
  106. 106.
    Pfizer. Solu-Medrol (methylprednisolone sodium succinate for injection) [package insert]. New York; 2011b.Google Scholar
  107. 107.
    Pfizer. Zinecard (dexrazoxane for injection) [package insert]. New York; 2012.Google Scholar
  108. 108.
    Pfizer Inc. Rapamune (sirolimus) [package insert]. Philadelphia; 2011.Google Scholar
  109. 109.
    Pharmacia & Upjohn Co. Zyvox (linezolid) [package insert]. New York; 2018.Google Scholar
  110. 110.
    Posteraro B, De Pascale G, Tumbarello M, Torelli R, Pennisi MA, Bello G, Maviglia R, Fadda G, Sanguinetti M, Antonelli M. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1-->3)-beta-D-glucan assay, Candida score, and colonization index. Crit Care. 2011;15(5):R249.  https://doi.org/10.1186/cc10507.CrossRefPubMedPubMedCentralGoogle Scholar
  111. 111.
    Radigan EA, Gilchrist NA, Miller MA. Management of aminoglycosides in the intensive care unit. J Intensive Care Med. 2010;25(6):327–42.  https://doi.org/10.1177/0885066610377968.CrossRefPubMedGoogle Scholar
  112. 112.
    Raptis A, Mavroudis D, Suffredini A, Molldrem J, Rhee FV, Childs R, Phang S, Barrett A. High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow stem cell transplant recipients. Bone Marrow Transplant. 1999;24(8):879–83.  https://doi.org/10.1038/sj.bmt.1701995.CrossRefPubMedGoogle Scholar
  113. 113.
    Rathi NK, Tanner AR, Dinh A, Dong W, Feng L, Ensor J, Wallace SK, Haque SA, Rondon G, Price KJ, Popat U, Nates JL. Low-, medium- and high-dose steroids with or without aminocaproic acid in adult hematopoietic SCT patients with diffuse alveolar hemorrhage. Bone Marrow Transplant. 2015;50(3):420–6.  https://doi.org/10.1038/bmt.2014.287.CrossRefPubMedGoogle Scholar
  114. 114.
    Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP. Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;45(3):486–552.  https://doi.org/10.1097/ccm.0000000000002255.CrossRefPubMedGoogle Scholar
  115. 115.
    Richards A, Marshall H, McQuary A. Evaluation of methylene blue, thiamine, and/or albumin in the prevention of ifosfamide-related neurotoxicity. J Oncol Pharm Pract. 2011;17(4):372–80.  https://doi.org/10.1177/1078155210385159.CrossRefPubMedGoogle Scholar
  116. 116.
    Richardson PG, Ho VT, Giralt S, Arai S, Mineishi S, Cutler C, Antin JH, Stavitzski N, Niederwieser D, Holler E, Carreras E, Soiffer R. Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease. Ther Adv Hematol. 2012;3(4):253–65.  https://doi.org/10.1177/2040620712441943.CrossRefPubMedPubMedCentralGoogle Scholar
  117. 117.
    Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, Arai S, Grupp SA, Guinan EC, Martin PL, Steinbach G, Krishnan A, Nemecek ER, Giralt S, Rodriguez T, Duerst R, Doyle J, Antin JH, Smith A, Lehmann L, Champlin R, Gillio A, Bajwa R, D'Agostino RB Sr, Massaro J, Warren D, Miloslavsky M, Hume RL, Iacobelli M, Nejadnik B, Hannah AL, Soiffer RJ. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127(13):1656–65.  https://doi.org/10.1182/blood-2015-10-676924.CrossRefPubMedPubMedCentralGoogle Scholar
  118. 118.
    Roberts I, Coats T, Edwards P, Gilmore I, Jairath V, Ker K, Manno D, Shakur H, Stanworth S, Veitch A. HALT-IT–tranexamic acid for the treatment of gastrointestinal bleeding: study protocol for a randomised controlled trial. Trials. 2014;15:450.  https://doi.org/10.1186/1745-6215-15-450.CrossRefPubMedPubMedCentralGoogle Scholar
  119. 119.
    Rybak JM, Marx KR, Nishimoto AT, Rogers PD. Isavuconazole: pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent. Pharmacotherapy. 2015;35(11):1037–51.  https://doi.org/10.1002/phar.1652.CrossRefPubMedGoogle Scholar
  120. 120.
    Sandherr M, Maschmeyer G. Pharmacology and metabolism of voriconazole and Posaconazole in the treatment of invasive aspergillosis: review of the literature. Eur J Med Res. 2011;16(4):139–44.CrossRefGoogle Scholar
  121. 121.
    Sanofi-Aventis. Elitek (rasburicase) [package insert]. Bridgewater; 2017.Google Scholar
  122. 122.
    Santabarbara G, Maione P, Rossi A, Gridelli C. Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy. Expert Opin Pharmacother. 2016;17(4):561–70.  https://doi.org/10.1517/14656566.2016.1122757.CrossRefPubMedGoogle Scholar
  123. 123.
    Segrelles Calvo G, De Granda-Orive I, Lopez Padilla D. Inhaled tranexamic acid as an alternative for hemoptysis treatment. Chest. 2016;149(2):604.  https://doi.org/10.1016/j.chest.2015.10.016.CrossRefPubMedGoogle Scholar
  124. 124.
    Shimabukuro-Vornhagen A, Boll B, Kochanek M, Azoulay E, von Bergwelt-Baildon MS. Critical care of patients with cancer. CA Cancer J Clin. 2016;  https://doi.org/10.3322/caac.21351.Google Scholar
  125. 125.
    Skiada A, Lanternier F, Groll AH, Pagano L, Zimmerli S, Herbrecht R, Lortholary O, Petrikkos GL. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica. 2013;98(4):492–504.  https://doi.org/10.3324/haematol.2012.065110.CrossRefPubMedPubMedCentralGoogle Scholar
  126. 126.
    Smith PF, Birmingham MC, Noskin GA, Meagher AK, Forrest A, Rayner CR, Schentag JJ. Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. Ann Oncol. 2003;14(5):795–801.CrossRefGoogle Scholar
  127. 127.
    Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol. 2015;33(28):3199–212.  https://doi.org/10.1200/jco.2015.62.3488.CrossRefPubMedGoogle Scholar
  128. 128.
    Soff GA, Miao Y, Devlin SM, Mantha S, Mones JV, Li VJ, Abou-Alfa GK, Cercek A, Kemeny N, Parameswara R. Romiplostim for chemotherapy-induced thrombcytopenia (CIT). Results of a phase 2 trial. Blood. 2017;130:289.Google Scholar
  129. 129.
    Soubani AO, Pandya CM. The spectrum of noninfectious pulmonary complications following hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther. 2010;3(3):143–57.CrossRefGoogle Scholar
  130. 130.
    Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988–1994. Clin Infect Dis. 2006;43(9):1143–51.  https://doi.org/10.1086/508173.CrossRefPubMedGoogle Scholar
  131. 131.
    Steinberg A, Gorman E, Tannenbaum J. Thiamine deficiency in stem cell transplant patients: a case series with an accompanying review of the literature. Clin Lymphoma Myeloma Leuk. 2014;14(Suppl):S111–3.  https://doi.org/10.1016/j.clml.2014.06.009.CrossRefPubMedGoogle Scholar
  132. 132.
    Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005;352(4):373–9.  https://doi.org/10.1056/NEJMcp042806.CrossRefPubMedGoogle Scholar
  133. 133.
    Tang Y, Wu Q, Wu X, Qiu H, Sun A, Ruan C, Wu D, Han Y. Use of recombinant factor VIIa in uncontrolled gastrointestinal bleeding after hematopoietic stem cell transplantation among patients with thrombocytopenia. Pak J Med Sci. 2015;31(6):1389–93.  https://doi.org/10.12669/pjms.316.8357.CrossRefPubMedPubMedCentralGoogle Scholar
  134. 134.
    Thachil J, Falanga A, Levi M, Liebman H, Di Nisio M. Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH. J Thromb Haemost. 2015;13(4):671–5.  https://doi.org/10.1111/jth.12838.CrossRefPubMedGoogle Scholar
  135. 135.
    Tizon R, Frey N, Heitjan DF, Tan KS, Goldstein SC, Hexner EO, Loren A, Luger SM, Reshef R, Tsai D, Vogl D, Davis J, Vozniak M, Fuchs B, Stadtmauer EA, Porter DL. High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT. Bone Marrow Transplant. 2012;47(10):1332–7.  https://doi.org/10.1038/bmt.2011.260.CrossRefPubMedGoogle Scholar
  136. 136.
    Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young J-A, Boeckh MJ. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone Marrow Transplant. 2009;44(8):453–558.CrossRefGoogle Scholar
  137. 137.
    Turner RB, Cumpston A, Sweet M, Briggs F, Slain D, Wen S, Craig M, Hamadani M, Petros W. Prospective, controlled study of acyclovir pharmacokinetics in obese patients. Antimicrob Agents Chemother. 2016;60(3):1830–3.  https://doi.org/10.1128/aac.02010-15.CrossRefPubMedPubMedCentralGoogle Scholar
  138. 138.
    UCB I. Keppra (levetiracetam) [package insert]. Smyrna; 2017.Google Scholar
  139. 139.
    Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335–47.  https://doi.org/10.1056/NEJMoa061098.CrossRefPubMedGoogle Scholar
  140. 140.
    Van Lint MT, Uderzo C, Locasciulli A, Majolino I, Scime R, Locatelli F, Giorgiani G, Arcese W, Iori AP, Falda M, Bosi A, Miniero R, Alessandrino P, Dini G, Rotoli B, Bacigalupo A. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood. 1998;92(7):2288–93.PubMedGoogle Scholar
  141. 141.
    Vecht CJ, Haaxma-Reiche H, van Putten WL, de Visser M, Vries EP, Twijnstra A. Initial bolus of conventional versus high-dose dexamethasone in metastatic spinal cord compression. Neurology. 1989;39(9):1255–7.CrossRefGoogle Scholar
  142. 142.
    Vecht CJ, van Breemen M. Optimizing therapy of seizures in patients with brain tumors. Neurology. 2006;67(12 Suppl 4):S10–3.CrossRefGoogle Scholar
  143. 143.
    Wanko SO, Broadwater G, Folz RJ, Chao NJ. Diffuse alveolar hemorrhage: retrospective review of clinical outcome in allogeneic transplant recipients treated with aminocaproic acid. Biol Blood Marrow Transplant. 2006;12(9):949–53.  https://doi.org/10.1016/j.bbmt.2006.05.012.CrossRefPubMedGoogle Scholar
  144. 144.
    West-Ward Pharmaceuticals. Allopurinol [package insert]. Eatontown; 2015.Google Scholar
  145. 145.
    Wilson DT, Dimondi VP, Johnson SW, Jones TM, Drew RH. Role of isavuconazole in the treatment of invasive fungal infections. Ther Clin Risk Manag. 2016;12:1197–206.  https://doi.org/10.2147/tcrm.S90335.CrossRefPubMedPubMedCentralGoogle Scholar
  146. 146.
    Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, Gersten ID, Mendizabal AM, Leather HL, Confer DL, Maziarz RT, Stadtmauer EA, Bolanos-Meade J, Brown J, Dipersio JF, Boeckh M, Marr KA. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116(24):5111–8.  https://doi.org/10.1182/blood-2010-02-268151.CrossRefPubMedPubMedCentralGoogle Scholar
  147. 147.
    Winter M. Basic and clinical pharmacokinetics. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2010. p. 263–70.Google Scholar
  148. 148.
    Woo M, Przepiorka D, Ippoliti C, Warkentin D, Khouri I, Fritsche H, Korbling M. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation. Bone Marrow Transplant. 1997;20(12):1095–8.  https://doi.org/10.1038/sj.bmt.1701027.CrossRefPubMedGoogle Scholar
  149. 149.
    Zeiser R, Blazar BR. Acute graft-versus-host disease – biologic process, prevention, and therapy. N Engl J Med. 2017;377(22):2167–79.  https://doi.org/10.1056/NEJMra1609337.CrossRefPubMedPubMedCentralGoogle Scholar
  150. 150.
    Juhl RC, Roddy JVF, Wang TF, Li J, Elefritz JL (2018) Thromboembolic complications following aminocaproic acid use in patients with hematologic malignancies. Leukemia & lymphoma:1–6.  https://doi.org/10.1080/10428194.2018.1434882.CrossRefGoogle Scholar

Copyright information

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2019

Authors and Affiliations

  • Anne Rain Tanner Brown
    • 1
    Email author
  • Michelle Horng
    • 1
  • Terri Lynn Shigle
    • 2
  1. 1.Clinical Pharmacy Specialist – Critical Care/Nutrition SupportThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Clinical Pharmacy Specialist – OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Section editors and affiliations

  • Todd W. Canada
    • 1
  • Jeffrey J. Bruno
    • 2
  1. 1.Clinical Pharmacy Svcs, Pharmacy Clinical ProgramsThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Clinical Pharmacy Specialist – Critical Care / Nutrition SupportThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations